Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.
Historically, RSV has been associated with infants, but they are not the only group that can be affected by serious RSV ...
Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...
Investor's Business Daily on MSN
Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust
Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.
Moderna’s highly touted cytomegalovirus vaccine — long billed as its next big win after its Covid-19 shot — failed a Phase 3 ...
A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback